IOL Chemicals and Pharmaceuticals Limited

BSE:524164 Stock Report

Market Cap: ₹24.0b

IOL Chemicals and Pharmaceuticals Past Earnings Performance

Past criteria checks 1/6

IOL Chemicals and Pharmaceuticals's earnings have been declining at an average annual rate of -29%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 3.3% per year. IOL Chemicals and Pharmaceuticals's return on equity is 6%, and it has net margins of 4.9%.

Key information

-29.0%

Earnings growth rate

-29.7%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate3.3%
Return on equity6.0%
Net Margin4.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How IOL Chemicals and Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:524164 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2420,5249982,1140
30 Jun 2420,7201,1852,0170
31 Mar 2421,3281,3442,0270
31 Dec 2322,1611,7161,9380
30 Sep 2322,1921,7231,8730
30 Jun 2322,1531,5031,7870
31 Mar 2322,1711,3911,6860
31 Dec 2222,0241,0411,6330
30 Sep 2222,3411,2041,5670
30 Jun 2222,3051,3531,5180
31 Mar 2221,8401,6771,4150
31 Dec 2120,7192,1321,3500
30 Sep 2120,2982,8791,2800
30 Jun 2120,2543,8401,2510
31 Mar 2119,6704,4461,1570
31 Dec 2019,4814,5961,1040
30 Sep 2019,4634,4281,0620
30 Jun 2018,6184,0359750
31 Mar 2018,9453,6139740
31 Dec 1918,7533,7279230
30 Sep 1918,4233,5699040
30 Jun 1918,1633,0768550
31 Mar 1916,8532,3677940
31 Dec 1815,5061,4657360
30 Sep 1813,3507316570
30 Jun 1811,2983916050
31 Mar 189,8332775620
31 Dec 178,8911785260
30 Sep 178,0941004950
30 Jun 178,26565260
31 Mar 177,107474330
31 Dec 166,595394360
30 Sep 166,197-744070
30 Jun 166,055-2143820
31 Mar 165,804-4003520
31 Dec 155,131-6923860
30 Sep 154,377-8903630
30 Jun 154,008-8582610
31 Mar 153,847-6672480
31 Dec 144,405-3782770
30 Sep 145,115-712810
30 Jun 145,452372710
31 Mar 145,635333980
31 Dec 135,684262670

Quality Earnings: 524164 has high quality earnings.

Growing Profit Margin: 524164's current net profit margins (4.9%) are lower than last year (7.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 524164's earnings have declined by 29% per year over the past 5 years.

Accelerating Growth: 524164's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 524164 had negative earnings growth (-42.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.4%).


Return on Equity

High ROE: 524164's Return on Equity (6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 22:22
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IOL Chemicals and Pharmaceuticals Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAntique Stockbroking Ltd.
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.
Kameswari V. S. ChavaliFirstCall Research